AMEX:VNRX

VolitionRx (NYSE American: VNRX) Downgraded to Hold by Freedom Broker Amidst Nu.Q Platform Progress

Font: Financial Modeling Prep  • Nov 18, 2026

Market Chart
  • Freedom Broker downgraded VolitionRx to Hold.
  • VolitionRx reports significant progress with its Nu.Q diagnostic platform, including peer-reviewed validation in sepsis and early-stage cancer detection above 95%.
  • The company expanded its Fujifilm agreement, reduced debt by over $5 million, and holds more than 70 patents for its platform.

VolitionRx (NYSE American: VNRX) develops the Nu.Q diagnostic platform. Freedom Broker downgraded VolitionRx to Hold when the stock was priced at $0.19. The shares trade at $0.19, down $0.01, or 5.56%, on volume of 3,018,250 shares.

The downgrade comes as VolitionRx reports progress across its Nu.Q product lines. Its 2026 work includes peer-reviewed validation in sepsis, early-stage cancer detection above 95% in a blinded cohort, and a government-funded sepsis program in France, as highlighted by PRNewsWire.

VolitionRx also expands its Fujifilm agreement to include cats and reduces debt by more than $5 million, as highlighted by PRNewsWire. The company is discussing licenses with more than a dozen diagnostic and liquid biopsy companies worldwide.

VolitionRx says more than 70 patents protect its platform. It aims to co-develop and license the technology in exchange for upfront payments, milestone payments and royalties. The stock’s one-year range is $0.16 to $7.80, and its market capitalization is about $2.27 million.

Market Overview
NVDA
NVIDIA Corporation
$150.96
-2.89%
LICN
Lichen International Limited
$0.02
-29.55%
CHSN
Chanson International Holding
$0.10
-78.30%
SOXL
Direxion Daily Semiconductor Bull 3X ETF
$49.26
0.39%
SVRE
SaverOne 2014 Ltd
$0.86
111.01%
SPDN
Direxion Daily S&P 500 Bear 1X ETF
$8.90
0.34%
AKAN
Akanda Corp.
$4.03
96.59%
INLF
INLIF Limited
$0.23
-36.81%
AES
The AES Corporation
$15.02
0.33%
GRAB
Grab Holdings Limited
$3.14
-1.26%